Is Buying Stock Like CytomX Therapeutics Inc (CTMX) After Such Increase Winning Strategy?

September 17, 2017 - By Marie Mckinney

The stock of CytomX Therapeutics Inc (NASDAQ:CTMX) is a huge mover today! The stock increased 4.28% or $0.71 on September 15, reaching $17.31. About 1.15 million shares traded or 298.68% up from the average. CytomX Therapeutics Inc (NASDAQ:CTMX) has risen 50.10% since September 17, 2016 and is uptrending. It has outperformed by 33.40% the S&P500.
The move comes after 5 months positive chart setup for the $638.17M company. It was reported on Sep, 17 by We have $18.52 PT which if reached, will make NASDAQ:CTMX worth $44.67 million more.

Analysts expect CytomX Therapeutics Inc (NASDAQ:CTMX) to report $-0.10 EPS on November, 2.They anticipate $0.30 EPS change or 75.00 % from last quarter’s $-0.4 EPS. After having $-0.69 EPS previously, CytomX Therapeutics Inc’s analysts see -85.51 % EPS growth.

CytomX Therapeutics Inc (NASDAQ:CTMX) Ratings Coverage

Among 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CytomX Therapeutics had 4 analyst reports since November 2, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, November 2 by Jefferies. Oppenheimer downgraded CytomX Therapeutics Inc (NASDAQ:CTMX) on Tuesday, January 3 to “Perform” rating. The firm has “Outperform” rating by Oppenheimer given on Monday, November 2. The stock of CytomX Therapeutics Inc (NASDAQ:CTMX) has “Outperform” rating given on Monday, November 2 by Cowen & Co.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The company has market cap of $638.17 million. The Firm uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. It currently has negative earnings. The Company’s pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: